The immunological basis of glutamatergic disturbance in schizophrenia: Towards an integrated view

Journal of Neural Transmission, Supplementa

Volumn , Issue 72, 2007, Pages 269-280

  Muller N ^a   Schwarz, M J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

COX 2; glutamate; immune system; NMDA receptor; PGE2; Schizophrenia

Indexed keywords

CARRIER PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DOPAMINE; DTNBP1 PROTEIN, HUMAN; GLUTAMINE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEU DIFFERENTIATION FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; UNCLASSIFIED DRUG;

ASTROCYTE; BRAIN; CEREBROSPINAL FLUID; DRUG ANTAGONISM; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PSYCHOLOGY; PSYCHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTROCYTES; BRAIN; CARRIER PROTEINS; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; DINOPROSTONE; DOPAMINE; GLUTAMINE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENIC ACID; NEUREGULINS; PSYCHONEUROIMMUNOLOGY; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TRYPTOPHAN; TRYPTOPHAN OXYGENASE;

EID: 38449100525     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-73574-9_33     Document Type: Review

References (122)

1. Aloisi F, Ria F, Adorini L (2000) Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 21:141-147
2. Andreasen NC, Rezai K, Alliger R, Swayze VW, Flaum M, Kirchner P, et al. (1992) Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 49:943-958
3. Avgustin B, Wraber B, Tavcar R (2005) Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat Med J 46:268-274
4. Bayer TA, Buslei R, Havas L, Falkai P (1999) Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 271:126-128
5. Bechter K, Schreiner V, Herzog S, Breitinger N, Wollinsky KH, Brinkmeier H, et al. (2003) CSF filtration as experimental therapy in therapyresistant psychoses in Borna disease virus-seropositive patients. Psychiatr Prax 30:216-220
6. Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M, et al. (2004) Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 61:774-780
7. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH (2001) Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 58:1032-1037
8. Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179-186
9. Carlsson A (2006) The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 39 Suppl 1: S10-S14
10. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41:237-260
11. Casolini P, Catalani A, Zuena AR, Angelucci L (2002) Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 68:337-343
12. Cazzullo CL, Scarone S, Grassi B, Vismara C, Trabattoni D, Clerici M, et al. (1998) Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog Neuropsychopharmacol Biol Psychiatry 22:947-957
13. Ceresoli-Borroni G, Rassoulpour A, Wu HQ, Guidetti P, Schwarcz R (2006) Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm 113(10):1355-1365
14. Chakos MH, Schobel SA, Gu H, Gerig G, Bradford D, Charles C, et al. (2005) Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br J Psychiatry 186:26-31
15. Chiang SSW, Riedel M, Müller N, Ackenheil M, Gruber R, Schwarz MJ (2004) Th2-shift in schizophrenia: primary findings from whole blood in vitro stimulation. Psychiatry Online
16. Chiarugi A, Carpenedo R, Moroni F (1996) Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase. J Neurochem 67:692-698
17. Collier DA, Li T (2003) The genetics of schizophrenia: glutamate not dopamine? Eur J Pharmacol 480:177-184
18. Cook GS, Hill DR (2001) Genetics of susceptibility to human infectious disease. Nat Rev Genet 2:967-977
19. Das I, Khan NS (1998) Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects. Prostaglandins Leukot Essent Fatty Acids 58:165-168
20. Dean K, Murray RM (2005) Environmental risk factors for psychosis. Dialogues Clin Neurosci 7:69-80
21. Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS (2006) Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 20:532-545
22. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G (2001a) Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 313:96-98
23. Erhardt S, Oberg H, Mathe JM, Engberg G (2001b) Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 20:353-362
24. Erhardt S, Schwieler L, Engberg G (2003) Kynurenic acid and schizophrenia. Adv Exp Med Biol 527:155-165
25. Farber NB, Wozniak DF, Price MT, Labruyere J, Huss J, St PH, et al. (1995) Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol Psychiatry 38:788-796
26. Fearon P, Cotter P, Murray RM (2000) Is the association between obstretic complications and schizophrenia mediated by glutaminergic excitotoxic damage of the foetal/neonatal brain? In: Revely M, Deacon B (eds), Psychopharmacology of schizophrenia. Chapman and Hall, London, 21-40
27. Ganguli R, Rabin BS, Kelly RH, Lyte M, Ragu U (1987) Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann NY Acad Sci 496:676-685
28. Gattaz WF, Abrahao AL, Foccacia R (2004) Childhood meningitis, brain maturation and the risk of psychosis. Eur Arch Psychiatry Clin Neurosci 254:23-26
29. Grohmann U, Fallarino F, Puccetti P (2003) Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 24:242-248
30. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis 17:455-461
31. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, et al. (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 78:842-853
32. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP (2002) Prostaglandins as modulators of immunity. Trends Immunol 23:144-150
33. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29-36
34. Heyes MP, Chen CY, Major EO, Saito K (1997) Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J 326:351-356
35. Hill AV (1996) Genetics of infectious disease resistance. Curr Opin Genet Dev 6:348-353
36. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463-7473
37. Huber G (1983) Das Konzept substratnaher Basissymptome und seine Bedeutung für Theorie und THerapie schizophrener Erkrankungen [The concept of substrate-close basic symptoms and its significance for the theory and therapy of schizophrenic diseases]. Nervenarzt 54:23-32
38. Jakob H, Beckmann H (1986) Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm 65:303-326
39. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225
40. Job DE, Whalley HC, McIntosh AM, Owens DG, Johnstone EC, Lawrie SM (2006) Grey matter changes can improve the prediction of schizophrenia in subjects at high risk. BMC Med 4:29
41. Kabiersch A, Furukawa H, del RA, Besedovsky HO (1998) Administration of interleukin-1 at birth affects dopaminergic neurons in adult mice. Ann NY Acad Sci 840:123-127
42. Kaiya H, Uematsu M, Ofuji M, Nishida A, Takeuchi K, Nozaki M, et al. (1989) Elevated plasma prostaglandin E2 levels in schizophrenia. J Neural Transm 77:39-46
43. Kegeles LS, bi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, et al. (2000) Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48:627-640
44. Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52:1319-1328
45. Kilidireas K, Latov N, Strauss DH, Gorig AD, Hashim GA, Gorman JM, et al. (1992) Antibodies to the human 60kDa heat-shock protein in patients with schizophrenia. Lancet 340:569-572
46. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20:379-382
47. Kim YK, Suh IB, Kim H, Han CS, Lim CS, Choi SH, et al. (2002) The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry 7:1107-1114
48. Kiss C, Ceresoli-Borroni G, Guidetti P, Zielke CL, Zielke HR, Schwarcz R (2003) Kynurenate production by cultured human astrocytes. J Neural Transm 110:1-14
49. Koponen H, Rantakallio P, Veijola J, Jones P, Jokelainen J, Isohanni M (2004) Childhood central nervous system infections and risk for schizophrenia. Eur Arch Psychiatry Clin Neurosci 254:9-13
50. Körschenhausen DA, Hampel HJ, Ackenheil M, Penning R, Müller N (1996) Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr Res 19:103-109
51. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
52. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, et al. (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235-9240
53. Laruelle M, Frankle WG, Narendran R, Kegeles LS, bi-Dargham A (2005) Mechanism of action of antipsychotic drugs: from dopamine D (2) receptor antagonism to glutamate NMDA facilitation. Clin Ther 27 Suppl A: S16-S24
54. Laumbacher B, Müller N, Bondy B, Schlesinger B, Gu S, Fellerhoff B, et al. (2003) Significant frequency deviation of the class I polymorphism HLA-A10 in schizophrenic patients. J Med Genet 40:217-219
55. Leweke FM, Gerth CW, Koethe D, Klosterkotter J, Ruslanova I, Krivogorsky B, et al. (2004) Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 254:4-8
56. Litherland SA, Xie XT, Hutson AD, Wasserfall C, Whittaker DS, She JX, et al. (1999) Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus. J Clin Invest 104:515-523
57. Maes M, Bosmans E, Kenis G, De Jong R, Smith RS, Meltzer HY (1997) In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 26:221-225
58. Marshall BE, Longnecker DE (1990) General anesthetics. In: Goodman LS, Gilman A, Rall TW, et al. (eds), The pharmacological basis of therapeutics. Pergamon Press, New York, pp 285-310
59. Meira-Lima IV, Pereira AC, Mota GF, Floriano M, Araujo F, Mansur AJ, et al. (2003) Analysis of a polymorphism in the promoter region of the tumor necrosis factor alpha gene in schizophrenia and bipolar disorder: further support for an association with schizophrenia. Mol Psychiatry 8:718-720
60. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S (2004) Expression of the kynurenine pathway enzyme tryptophan 2, 3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 15:618-629
61. Miller CL, Llenos IC, Dulay JR, Weis S (2006) Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 1073-1074:25-37
62. Miller DW, Abercrombie ED (1996) Effects of MK-801on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res Bull 40:57-62
63. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM (2000) M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 164:6166-6173
64. Mittleman BB, Castellanos FX, Jacobsen LK, Rapoport JL, Swedo SE, Shearer GM (1997) Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 159:2994-2999
65. Molholm HB (1942) Hyposensitivity to foreign protein in schizophrenic patients. Psychiatr Quart 16:565-571
66. Müller N (2004) Immunological and infectious aspects of schizophrenia. Eur Arch Psychiatry Clin Neurosci 254:1-3
67. Müller N, Ackenheil M, Hofschuster E, Mempel W, Eckstein R (1991) Cellular immunity in schizophrenic patients before and during neuroleptic treatment. Psychiatry Res 37:147-160
68. Müller N, Ackenheil M (1995) Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology. Schizophr Res 14:223-228
69. Müller N, Empl M, Riedel M, Schwarz M, Ackenheil M (1997a) Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 247:308-313
70. Müller N, Riedel M, Schwarz MJ, et al. (1997b) Immunomodulatory effects of neuroleptics to the cytokine system and the cellular immune system in schizophrenia. In: Wieselmann G (ed), Current update in psychoimmunology. Springer, Wien New York, pp 57-67
71. Müller N, Ackenheil M (1998) Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 22:1-33
72. Müller N, Riedel M, Hadjamu M, Schwarz MJ, Ackenheil M, Gruber R (1999) Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am J Psychiatry 156:634-636
73. Müller N, Riedel M, Ackenheil M, Schwarz MJ (2000) Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation. World J Biol Psychiatry 1:173-179
74. Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, et al. (2002) Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 159:1029-1034
75. Müller N, Riedel M, Schwarz MJ (2004a) Psychotropic effects of COX-2 inhibitors - a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 37:266-269
76. Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller HJ, et al. (2004b) COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci 254:14-22
77. Müller N, Riedel M, Schwarz MJ, Engel RR (2005) Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 255:149-151
78. Murray RM, Lewis SW (1987) Is schizophrenia a neurodevelopmental disorder? Br Med J (Clin Res Ed) 295:681-682
79. Numakawa T, Yagasaki Y, Ishimoto T, Okada T, Suzuki T, Iwata N, et al. (2004) Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet 13:2699-2708
80. Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007
81. Ozek M, Toreci K, Akkok I, Guvener Z (1971) [Influence of therapy on antibody-formation]. Psychopharmacologia 21:401-412
82. Pearce BD (2001) Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms. Mol Psychiatry 6:634-646
83. Pilowsky LS, Bressan RA, Stone JM, Erlandsson K, Mulligan RS, Krystal JH, et al. (2006) First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 11:118-119
84. Pyeon D, Diaz FJ, Splitter GA (2000) Prostaglandin E (2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus. J Virol 74:5740-5745
85. Rapaport MH, Müller N (2001) Immunological states associated with schizophrenia. In: Ader A, Felten DL, Cohnen N (eds), Psychoneuroimmunology, vol 2, 3rd edn. Academic Press, San Diego, CA, pp 373-382
86. Riedel M, Krönig H, Schwarz MJ, Engel RR, Kuhn KU, Sikorski C, et al. (2002) No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia. Eur Arch Psychiatry Clin Neurosci 252:232-234
87. Riedel M, Spellmann I, Schwarz MJ, Strassnig M, Sikorski C, Möller HJ, et al. (2006) Decreased T cellular immune response in schizophrenic patients. J Psychiatr Res 41:3-7
88. Rothermundt M, Arolt V, Bayer TA (2001) Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 15:319-339
89. Rothermundt M, Falkai P, Ponath G, Abel S, Burkle H, Diedrich M, et al. (2004a) Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 9:897-899
90. Rothermundt M, Ponath G, Arolt V (2004b) S100B in schizophrenic psychosis. Int Rev Neurobiol 59:445-470
91. Schuld A, Hinze-Selch D, Pollmacher T (2004) Zytokinnetzwerke bei Patienten mit Schizophrenie und ihre Bedeutung für die Pathophysiologie der Erkrankung [Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness]. Nervenarzt 75:215-226
92. Schwab SG, Hallmayer J, Albus M, Lerer B, Eckstein GN, Borrmann M, et al. (2000) A genome-wide autosomal screen for schizophrenia susceptibility loci in 71 families with affected siblings: support for loci on chromosome 10p and 6. Mol Psychiatry 5:638-649
93. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521-530
94. Schwarcz R, Pellicciari R (2002) Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 303:1-10
95. Schwarz MJ, Riedel M, Gruber R, Ackenheil M, Müller N (1999) Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease. Am J Psychiatry 156:1103-1104
96. Schwarz MJ, Riedel M, Ackenheil M, Müller N (2000) Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol Psychiatry 47:29-33
97. Schwarz MJ, Chiang S, Müller N, Ackenheil M (2001) T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav Immun 15:340-370
98. Schwarz MJ, Kronig H, Riedel M, Dehning S, Douhet A, Spellmann I, et al. (2005) IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur Arch Psychiatry Clin Neurosci 256(2):72-76
99. Schwieler L, Engberg G, Erhardt S (2004) Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse 52:114-122
100. Schwieler L, Erhardt S, Erhardt C, Engberg G (2005) Prostaglandinmediated control of rat brain kynurenic acid synthesis - opposite actions by COX-1 and COX-2 isoforms. J Neural Transm 112:863-872
101. Speciale C, Schwarcz R (1993) On the production and disposition of quinolinic acid in rat brain and liver slices. J Neurochem 60:212-218
102. Speciale C, Wu HQ, Cini M, Marconi M, Varasi M, Schwarcz R (1996) (R, S)-3, 4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur J Pharmacol 315:263-267
103. Sperner-Unterweger B, Miller C, Holzner B, et al. (1999) Measurement of neopterin, kynurenine and tryptophan in sera of schizophrenic patients. In: Müller N (ed), Psychiatry, psychoimmunology and viruses. Springer, Wien New York, pp 115-119
104. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, et al. (2000) Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164:361-370
105. Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309-379
106. Stoy N, Mackay GM, Forrest CM, Christofides J, Egerton M, Stone TW, et al. (2005) Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem 93:611-623
107. Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY (2004) Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropsychopharmacol 7:1-8
108. Sumiyoshi T, Jin D, Jayathilake K, Lee M, Meltzer HY (2005) Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. Int J Neuropsychopharmacol 8:451-455
109. Takikawa O, Yoshida R, Kido R, Hayaishi O (1986) Tryptophan degradation in mice initiated by indoleamine 2, 3-dioxygenase. J Biol Chem 261:3648-3653
110. Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ, et al. (2004) Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 113:1353-1363
111. Tamminga CA, Cascella N, Fakouhl TD, et al. (1992) Enhancement of NMDA-mediated transmission in schizophrenia: effects of milacemide. In: Meltzer HY (ed), Novel antipsychotic drugs. Raven Press, New York, pp 171-177
112. Tanaka KF, Shintani F, Fujii Y, Yagi G, Asai M (2000) Serum interleukin-18 levels are elevated in schizophrenia. Psychiatry Res 96:75-80
113. Torrey EF, Miller J, Rawlings R, Yolken RH (1997) Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr Res 28:1-38
114. van Kammen DP, McAllister-Sistilli CG, Kelley ME (1997) Relationship between immune and behavioral measures in schizophrenia. In: Wieselmann G (ed), Current update in psychoimmunology. Springer, Wien New York, pp 51-55
115. Westergaard T, Mortensen PB, Pedersen CB, Wohlfahrt J, Melbye M (1999) Exposure to prenatal and childhood infections and the risk of schizophrenia: suggestions from a study of sibship characteristics and influenza prevalence. Arch Gen Psychiatry 56:993-998
116. Wilke I, Arolt V, Rothermundt M, Weitzsch C, Hornberg M, Kirchner H (1996) Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 246:279-284
117. Williams NM, Preece A, Spurlock G, Norton N, Williams HJ, Zammit S, et al. (2003) Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Mol Psychiatry 8:485-487
118. Wu HQ, Rassoulpour A, Schwarcz R (2006) Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain? J Neural Transm
119. Xiao BG, Link H (1999) Is there a balance between microglia and astrocytes in regulating Th1/Th2-cell responses and neuropathologies? Immunol Today 20:477-479
120. Yokota O, Terada S, Ishihara T, Nakashima H, Kugo A, Ujike H, et al. (2004) Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:715-721
121. Yolken RH, Torrey EF (1995) Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev 8:131-145
122. Zuckerman L, Weiner I (2005) Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res 39:311-323